Sastasundar Ventures Ltd
Incorporated in 1989, Sastasundar Ventures Ltd is in the business of digital network of healthcare and portfolio management services[1]
- Market Cap ₹ 901 Cr.
- Current Price ₹ 283
- High / Low ₹ 375 / 205
- Stock P/E
- Book Value ₹ 85.3
- Dividend Yield 0.00 %
- ROCE -0.26 %
- ROE -0.26 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.32 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -0.27% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.67 | 2.29 | 2.10 | 0.98 | 1.43 | 2.47 | 0.31 | 0.28 | 0.19 | 0.25 | 0.45 | 0.44 | 0.39 | |
| 2.14 | 2.00 | 2.00 | 1.77 | 1.90 | 1.88 | 1.33 | 0.90 | 1.04 | 1.41 | 1.93 | 1.79 | 1.59 | |
| Operating Profit | 0.53 | 0.29 | 0.10 | -0.79 | -0.47 | 0.59 | -1.02 | -0.62 | -0.85 | -1.16 | -1.48 | -1.35 | -1.20 |
| OPM % | 19.85% | 12.66% | 4.76% | -80.61% | -32.87% | 23.89% | -329.03% | -221.43% | -447.37% | -464.00% | -328.89% | -306.82% | -307.69% |
| 0.09 | 0.16 | -2.26 | -1.34 | 14.00 | 0.22 | 1.87 | 0.68 | 0.72 | 2.00 | 0.73 | 0.76 | 0.48 | |
| Interest | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.06 |
| Depreciation | 0.36 | 0.41 | 0.34 | 0.27 | 0.23 | 0.21 | 0.18 | 0.17 | 0.18 | 0.16 | 0.10 | 0.10 | 0.08 |
| Profit before tax | 0.24 | 0.02 | -2.52 | -2.43 | 13.28 | 0.58 | 0.64 | -0.14 | -0.34 | 0.65 | -0.89 | -0.72 | -0.86 |
| Tax % | -141.67% | -5,200.00% | -17.86% | 0.00% | 14.83% | 39.66% | 0.00% | 0.00% | 14.71% | 0.00% | 0.00% | 0.00% | |
| 0.59 | 1.05 | -2.07 | -2.44 | 11.32 | 0.36 | 0.64 | -0.14 | -0.39 | 0.65 | -0.89 | -0.71 | -0.87 | |
| EPS in Rs | 0.19 | 0.33 | -0.65 | -0.77 | 3.56 | 0.11 | 0.20 | -0.04 | -0.12 | 0.20 | -0.28 | -0.22 | -0.27 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -15% |
| 5 Years: | 7% |
| 3 Years: | 32% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -42% |
| TTM: | -23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 6% |
| 1 Year: | 30% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 |
| Reserves | 193.32 | 194.15 | 192.08 | 189.64 | 240.01 | 240.96 | 241.59 | 241.44 | 241.00 | 241.61 | 240.72 | 239.99 | 239.60 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 1.81 | 0.64 | 0.36 | 1.81 | 0.79 | 6.03 | 0.56 | 0.27 | 0.30 | 0.43 | 0.40 | 0.36 | 0.34 | |
| Total Liabilities | 226.94 | 226.60 | 224.25 | 223.26 | 272.61 | 278.80 | 273.96 | 273.52 | 273.11 | 273.85 | 272.93 | 272.16 | 271.75 |
| 4.40 | 3.83 | 4.47 | 4.19 | 4.17 | 3.95 | 3.40 | 3.24 | 3.12 | 2.13 | 2.02 | 1.94 | 1.89 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 215.59 | 219.66 | 217.29 | 217.69 | 259.11 | 274.15 | 269.56 | 269.43 | 264.98 | 265.60 | 264.87 | 264.64 | 264.78 |
| 6.95 | 3.11 | 2.49 | 1.38 | 9.33 | 0.70 | 1.00 | 0.85 | 5.01 | 6.12 | 6.04 | 5.58 | 5.08 | |
| Total Assets | 226.94 | 226.60 | 224.25 | 223.26 | 272.61 | 278.80 | 273.96 | 273.52 | 273.11 | 273.85 | 272.93 | 272.16 | 271.75 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.57 | -4.06 | -0.01 | 1.27 | -9.20 | 3.61 | -0.83 | -0.51 | -0.52 | -0.63 | -1.21 | -5.51 | |
| -3.72 | 3.94 | 0.23 | -1.00 | 12.34 | -7.62 | 0.97 | 0.47 | 0.54 | 0.64 | 1.09 | 5.45 | |
| -0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | -0.20 | -0.12 | 0.22 | 0.28 | 3.14 | -4.01 | 0.14 | -0.04 | 0.02 | 0.02 | -0.11 | -0.06 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 6.38 | 0.00 | 14.90 | 206.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 6.38 | 0.00 | 14.90 | 206.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Days | -185.92 | -65.35 | -38.24 | -610.82 | 1,079.69 | -799.45 | 259.03 | 521.43 | 8,663.95 | 7,986.20 | 4,485.44 | 730.00 |
| ROCE % | 0.12% | 0.02% | -0.06% | -0.48% | -0.25% | 0.15% | -0.23% | -0.04% | -0.12% | -0.21% | -0.31% | -0.26% |
Documents
Announcements
-
Disclosure under Regulation 30A of LODR
10h - Tripartite Agreement: Envision acquires Mitsubishi's SHBL stake; scheme to merge SHBL into HealthX; Envision may get board seat.
-
Disclosure Under Reg 30(9) Of SEBI (LODR) - Intimation By Sastasundar Healthbuddy Limited, Material Subsidiary Regarding Outcome Of Its Board Meeting
10h - Envision to acquire Mitsubishi's SHBL shares (SPA 25 Feb 2026); tripartite agreement for merger/share-swap; board appointment rights.
-
Board Meeting Outcome for Disclosure Under Reg 30 Of SEBI (LODR) - Outcome Of Meeting Of The Board
12h - Board approved tripartite agreement: Envision acquires Mitsubishi's SHBL stake (SPA 25-Feb-2026); merger or share-swap into HealthX.
-
Disclosure Under Reg 30 (LODR) - Intimation By Sastasundar Healthbuddy Limited, Material Subsidiary Regarding Outcome Of Its Board Meeting
1d - SHBL approved in-principle merger into Health X Platform; contingent on Mitsubishi sale to Envision (SPA dated 25.02.2026).
-
Board Meeting Outcome for Disclosure Under Reg 30 Of SEBI (LODR) - Outcome Of Meeting Of The Board
1d - Board approved in‑principle merger of SHBL into HealthX; contingent on Mitsubishi sale to Envision (SPA dated 25-02-2026).
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Concalls
-
Feb 2026Transcript PPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jul 2023TranscriptAI SummaryPPT
-
Mar 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Jun 2022TranscriptAI SummaryPPT
-
Mar 2022TranscriptAI SummaryPPT
-
Dec 2021TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Aug 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
Business Overview:[1][2][3]
SSVL, a Core Investment Company (CIC), operates through multiple subsidiaries and offers a digital platform for pharmacy, wellness, and diagnostics, serving both B2B and B2C segments with person-centric healthcare solutions.